ObsEva SA (NASDAQ:OBSV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
Several other brokerages have also weighed in on OBSV. HC Wainwright initiated coverage on ObsEva SA in a research report on Thursday, June 29th. They issued a “buy” rating and a $27.00 target price on the stock. Credit Suisse Group reaffirmed an “outperform” rating and issued a $27.00 target price on shares of ObsEva SA in a research report on Tuesday, April 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $24.00.
ObsEva SA (NASDAQ OBSV) opened at 8.33 on Wednesday. The firm’s market capitalization is $246.83 million. ObsEva SA has a 1-year low of $5.00 and a 1-year high of $14.69. The stock has a 50 day moving average price of $7.31 and a 200 day moving average price of $9.35.
ObsEva SA (NASDAQ:OBSV) last issued its earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.17. Analysts predict that ObsEva SA will post ($2.04) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/07/19/obseva-sa-obsv-upgraded-to-hold-by-zacks-investment-research.html.
Several hedge funds have recently added to or reduced their stakes in OBSV. NEA Management Company LLC bought a new stake in ObsEva SA during the first quarter valued at about $34,734,000. Sphera Funds Management LTD. bought a new stake in ObsEva SA during the first quarter valued at about $2,197,000. UBS Oconnor LLC bought a new stake in ObsEva SA during the first quarter valued at about $1,017,000. Citadel Advisors LLC bought a new stake in ObsEva SA during the first quarter valued at about $937,000. Finally, Nexthera Capital LP bought a new stake in ObsEva SA during the first quarter valued at about $521,000. Institutional investors own 49.24% of the company’s stock.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Get a free copy of the Zacks research report on ObsEva SA (OBSV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.
